
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The companys approach is to use replacement therapies substrates, enzymes, or proteins and to target those molecules to clinically relevant cellular compartments. Glycomines lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need
Glycomine inc operates in the Biotechnology research industry.
Glycomine inc's revenue is 1m - 10m
Glycomine inc has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.